EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Peptide RF16 Derived from CXCL8 Inhibits MDA-MB-231 Cell Invasion and Metastasis

Chun-Ming Chang, Chun-Chun Chang, Ho Yin Pekkle Lam iD, Shih-Yi Peng iD, Yi-Hsuan Lai, Bi-Da Hsiang iD, Yu-Yi Liao, Hao-Jen Hsu iD, Shinn-Jong Jiang iD

International Journal of Molecular Sciences · 13.09.2023 · 24 (18) · 14029

DOI: 10.3390/ijms241814029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.09.2023. Verfasst von Chun-Ming Chang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Buddhist Tzu Chi Medical Foundation, Ministry of Science and Technology Taiwan, Ministry of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Interleukin (IL)-8 plays a vital role in regulating inflammation and breast cancer formation by activating CXCR1/2. We previously designed an antagonist peptide, (RF16), to inhibits the activation of downstream signaling pathways by competing with IL-8 in binding to CXCR1/2, thereby inhibiting IL-8-induced chemoattractant monocyte binding. To evaluate the effect of the RF16 peptide on breast cancer progression, triple-negative MDA-MB-231 and ER-positive MCF-7 breast cancer cells were used to investigate whether RF16 can inhibit the IL-8-induced breast cancer metastasis. Using growth, proliferation, and invasiveness assays, the results revealed that RF16 reduced cell proliferation, migration, and invasiveness in MDA-MB-231 cells. The RF16 peptide also regulated the protein and mRNA expressions of epithelial–mesenchymal transition (EMT) markers in IL-8-stimulated MDA-MB-231 cells. It also inhibited downstream IL-8 signaling and the IL-8-induced inflammatory response via the mitogen-activated protein kinase (MAPK) and Phosphoinositide 3-kinase (PI3K) pathways. In the xenograft tumor mouse model, RF16 synergistically reinforces the antitumor efficacy of docetaxel by improving mouse survival and retarding tumor growth. Our results indicate that RF16 significantly inhibited IL-8-stimulated cell growth, migration, and invasion in MDA-MB-231 breast cancer cells by blocking the activation of p38 and AKT cascades. It indicated that the RF16 peptide may serve as a new supplementary drug for breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTriple Negative Breast NeoplasmsHumansAnimalsMiceFemaleMDA-MB-231 CellsPhosphatidylinositol 3-KinasesInterleukin-8Signal TransductionCell ProliferationCell Line, TumorCell MovementEpithelial-Mesenchymal Transition

Stichwörter der Autor:innen

IL-8breast cancercell proliferationinvasivenessmetastasispeptide drugs

Substanzen

Phosphatidylinositol 3-KinasesInterleukin-8

Autor:innen und Institutionen

  • Department of General Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.
  • Institute of Medical Sciences, Tzu Chi University, Hualien 97004, Taiwan.
  • Department of Laboratory Medicine, Hualien Tzu Chi Hospital, Hualien 97004, Taiwan.
  • Department of Laboratory Medicine and Biotechnology, College of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
  • Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
  • Master Program in Biomedical Sciences, School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.

ORCID-Profile: Ho Yin Pekkle Lam, Shih-Yi Peng, Bi-Da Hsiang, Hao-Jen Hsu, Shinn-Jong Jiang

Förderung

  • Buddhist Tzu Chi Medical Foundation
  • Ministry of Science and Technology Taiwan
  • Ministry of Science and Technology

Zitieren

APA

Chang, C. M., Chang, C. C., Lam, H. Y. P., Peng, S. Y., Lai, Y. H., Hsiang, B. D., Liao, Y. Y., Hsu, H. J., & Jiang, S. J. (2023). Therapeutic Peptide RF16 Derived from CXCL8 Inhibits MDA-MB-231 Cell Invasion and Metastasis. International Journal of Molecular Sciences, 24(18), 14029. https://doi.org/10.3390/ijms241814029

Vancouver

Chang CM, Chang CC, Lam HYP, Peng SY, Lai YH, Hsiang BD, et al. Therapeutic Peptide RF16 Derived from CXCL8 Inhibits MDA-MB-231 Cell Invasion and Metastasis. International Journal of Molecular Sciences. 2023;24(18):14029. doi:10.3390/ijms241814029

BibTeX
@article{Chang2023,
  author = {Chang, Chun-Ming and Chang, Chun-Chun and Lam, Ho Yin Pekkle and Peng, Shih-Yi and Lai, Yi-Hsuan and Hsiang, Bi-Da and Liao, Yu-Yi and Hsu, Hao-Jen and Jiang, Shinn-Jong},
  title = {Therapeutic Peptide RF16 Derived from CXCL8 Inhibits MDA-MB-231 Cell Invasion and Metastasis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {18},
  pages = {14029},
  doi = {10.3390/ijms241814029}
}
Kostenlos starten →